TRIMTECH forms scientific advisory board

TRIMTECH Therapeutics Ltd has formed a scientific advisory board to support the UK company’s protein degradation technology and develop new drugs for neurodegenerative diseases. The board chair, Alessio Ciulli, is the founder and director of the Centre for Targeted Protein Degradation at the University of Dundee, UK. Adam Gilbert, a board member, has over 30 years of experience in pharma, including as executive director of design and synthesis sciences at Pfizer Inc. He is currently a scientific advisor to Axiom Therapeutics, PhoreMost and Gero.AI. TRIMTECH has a pipeline of small molecule candidate therapies for disorders including Alzheimer’s and Huntington’s diseases.